Current status and clinical outcome of endoscopic hemostatic powder in gastrointestinal bleeding: a retrospective multicenter study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Few multicenter studies have investigated the efficacy of hemostatic powders in gastrointestinal (GI) bleeding. We aimed to investigate the clinical outcomes of hemostatic powder therapy and the independent factors affecting rebleeding rates. Methods: We retrospectively recruited patients who underwent a new hemostatic adhesive powder (UI-EWD; Next-Biomedical) treatment for upper and lower GI bleeding between January 1, 2020 and March 1, 2023. We collected patients’ medical records and bleeding lesions. The primary outcomes were clinical and technical success rates, and the secondary outcomes were early and delayed bleeding rates refractory bleeding rate, mortality rate, and factors affecting early rebleeding rates. Results: This study enrolled 135 patients (age: 67.7±13.6 years, male: 74.1%) from five hospitals. Indications for UI-EWD were peptic ulcers (51.1%), post-procedure-related bleeding (23.0%), and tumor bleeding (19.3%). The clinical and technical success rates were both 97%. The early, delayed, and refractory rebleeding rates were 19.3%, 11.1%, and 12.8%, respectively. Initially elevated blood urea nitrogen (BUN) levels (p=0.014) and Forrest classification IA or IB compared with IIA or IIB (p=0.036) were factors affecting early rebleeding. Conclusions: UI-EWD showed high clinical and technical success rates; however, rebleeding after UI-EWD therapy in patients with initially high BUN levels and active bleeding, according to the Forrest classification, should be considered.
Abstract
Background/Aims: Few multicenter studies have investigated the efficacy of hemostatic powders in gastrointestinal (GI) bleeding. We aimed to investigate the clinical outcomes of hemostatic powder therapy and the independent factors affecting rebleeding rates. Methods: We retrospectively recruited patients who underwent a new hemostatic adhesive powder (UI-EWD; Next-Biomedical) treatment for upper and lower GI bleeding between January 1, 2020 and March 1, 2023. We collected patients’ medical records and bleeding lesions. The primary outcomes were clinical and technical success rates, and the secondary outcomes were early and delayed bleeding rates refractory bleeding rate, mortality rate, and factors affecting early rebleeding rates. Results: This study enrolled 135 patients (age: 67.7±13.6 years, male: 74.1%) from five hospitals. Indications for UI-EWD were peptic ulcers (51.1%), post-procedure-related bleeding (23.0%), and tumor bleeding (19.3%). The clinical and technical success rates were both 97%. The early, delayed, and refractory rebleeding rates were 19.3%, 11.1%, and 12.8%, respectively. Initially elevated blood urea nitrogen (BUN) levels (p=0.014) and Forrest classification IA or IB compared with IIA or IIB (p=0.036) were factors affecting early rebleeding. Conclusions: UI-EWD showed high clinical and technical success rates; however, rebleeding after UI-EWD therapy in patients with initially high BUN levels and active bleeding, according to the Forrest classification, should be considered.
참고문헌 (23)
- Bong SH, "Bleeding on the edge-the use of hemostatic powder for treating a bleeding hypopharyngeal tumor", Clin Endosc, 54, pp.441~442 (2021)
- Sung JJ, "Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding : an update 2018", Gut, 67, pp.1757~1768 (2018)
- Aziz M, "Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding : a systematic review with meta-analysis", Ann Gastroenterol, 33, pp.145~154 (2020)
- Cha B, "Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding", BMC Gastroenterol, 22, pp.170~ (2022)
- Park JS, "Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding : a pilot study", Endoscopy, 51, pp.458~462 (2019)
- Park JS, "Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding", Endosc Int Open, 7, pp.E1763~E1767 (2019)
- Jung DH, "Polysaccharide hemostatic powder to prevent bleeding after endoscopic submucosal dissection in high risk patients : a randomized controlled trial", Endoscopy, 53, pp.994~1002 (2021)
- Park JC, "Effectiveness of the polysaccharide hemostatic powder in non-variceal upper gastrointestinal bleeding : using propensity score matching", J Gastroenterol Hepatol, 33, pp.1500~1506 (2018)
- Bang BW, "CEGP-003 spray has a similar hemostatic effect to epinephrine injection in cases of acute upper gastrointestinal bleeding", Dig Dis Sci, 63, pp.3026~3032 (2018)
- Baracat FI, "Randomized controlled trial of hemostatic powder versus endoscopic clipping for non-variceal upper gastrointestinal bleeding", Surg Endosc, 34, pp.317~324 (2020)
- Lau JY, "Comparison of a hemostatic powder and standard treatment in the control of active bleeding from upper nonvariceal lesions : a multicenter, noninferiority, randomized trial", Ann Intern Med, 175, pp.171~178 (2022)
- Mutneja H, "Efficacy of hemospray in upper gastrointestinal bleeding : a systematic review and meta-analysis", J Gastrointestin Liver Dis, 29, pp.69~76 (2020)
- Ofosu A, "The efficacy and safety of hemospray for the management of gastrointestinal bleeding : a systematic review and meta-analysis", J Clin Gastroenterol, 55, pp.e37~e45 (2021)
- Sung JJ, "Use of topical mineral powder as monotherapy for treatment of active peptic ulcer bleeding", Gas trointest Endosc, 96, pp.28~35 (2022)
- Rodríguez de Santiago E, "Hemostatic spray powder TC-325 for GI bleeding in a nationwide study : survival and predictors of failure via competing risks analysis", Gastrointest Endosc, 90, pp.581~590 (2019)
- Shin J, "Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding", BMC Gastroenterol, 21, pp.40~ (2021)
- Gralnek IM, "Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage(NVUGIH) : European Society of Gastrointestinal Endoscopy(ESGE)Guideline : Update 2021", Endoscopy, 53, pp.300~332 (2021)
- Laine L, "ACG clinical guideline : upper gastrointestinal and ulcer bleeding", Am J Gastroenterol, 116, pp.899~917 (2021)
- Galloro G, "Endoscopic clipping in non-var iceal upper gastrointestinal bleeding treatment", Clin Endosc, 55, pp.339~346 (2022)
- de Groot NL, "Reassessment of the predictive value of the Forrest classification for peptic ulcer re bleeding and mortality : can classification be simplified?", Endoscopy, 46, pp.46~52 (2014)
- Bryant RV, "Performance of the Glasgow-Blatchford score in predicting clinical outcomes and intervention in hospitalized patients with upper GI bleeding", Gastrointest Endosc, 78, pp.576~583 (2013)
- Stanley AJ, "Update on risk scoring systems for patients with upper gastrointestinal haemorrhage", World J Gastroenterol, 18, pp.27392744~ (2012)
- Chang A, "Prospective comparison of the AIMS65 score, Glasgow-Blatchford score, and Rockall score for predicting clinical outcomes in patients with var iceal and nonvariceal upper gastrointestinal bleeding", Clin Endosc, 54, pp.211~221 (2021)